CA2572770A1 - Polypeptide protracting tags comprising a tetrazole moiety - Google Patents

Polypeptide protracting tags comprising a tetrazole moiety Download PDF

Info

Publication number
CA2572770A1
CA2572770A1 CA 2572770 CA2572770A CA2572770A1 CA 2572770 A1 CA2572770 A1 CA 2572770A1 CA 2572770 CA2572770 CA 2572770 CA 2572770 A CA2572770 A CA 2572770A CA 2572770 A1 CA2572770 A1 CA 2572770A1
Authority
CA
Canada
Prior art keywords
glp
ethoxy
peptide
tetrazol
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2572770
Other languages
English (en)
French (fr)
Inventor
Florencio Zaragoza Doerwald
Christine Bruun Schiodt
Thomas Kruse Hansen
Kjeld Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2572770A1 publication Critical patent/CA2572770A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
CA 2572770 2004-07-08 2005-06-21 Polypeptide protracting tags comprising a tetrazole moiety Abandoned CA2572770A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200401083 2004-07-08
DKPA200401083 2004-07-08
EP05102167 2005-03-18
EP05102167.3 2005-03-18
PCT/EP2005/052874 WO2006005667A2 (en) 2004-07-08 2005-06-21 Polypeptide protracting tags comprising a tetrazole moiety

Publications (1)

Publication Number Publication Date
CA2572770A1 true CA2572770A1 (en) 2006-01-19

Family

ID=35453538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2572770 Abandoned CA2572770A1 (en) 2004-07-08 2005-06-21 Polypeptide protracting tags comprising a tetrazole moiety

Country Status (12)

Country Link
US (2) US20090111730A1 (enExample)
EP (3) EP2292272A3 (enExample)
JP (1) JP2008507477A (enExample)
KR (1) KR20070029247A (enExample)
CN (1) CN101005857A (enExample)
AU (1) AU2005261740A1 (enExample)
BR (1) BRPI0512988A (enExample)
CA (1) CA2572770A1 (enExample)
ES (2) ES2542228T3 (enExample)
MX (1) MXPA06015049A (enExample)
RU (1) RU2006144821A (enExample)
WO (1) WO2006005667A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007011307A (es) * 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
EP1996617A2 (en) * 2006-03-15 2008-12-03 Novo Nordisk A/S Amylin derivatives
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
US20100056433A1 (en) * 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087190A2 (en) * 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
EP2106407A2 (en) * 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
US20100016237A1 (en) * 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087187A1 (en) * 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
JP5606314B2 (ja) * 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー／エス Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
EP2190873B1 (en) * 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN101981050A (zh) 2008-01-23 2011-02-23 诺沃-诺迪斯克保健股份有限公司 新的凝血因子抑制剂
KR20110004366A (ko) 2008-03-18 2011-01-13 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
KR20110017874A (ko) * 2008-05-16 2011-02-22 노보 노르디스크 에이/에스 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제
EP2283037A1 (en) * 2008-05-22 2011-02-16 Novo Nordisk A/S Process
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
ES2662501T3 (es) 2008-10-21 2018-04-06 Novo Nordisk A/S Derivados de amilina
WO2010076809A2 (en) * 2008-12-29 2010-07-08 Panacea Biotec Ltd Glp-1 analogs and uses thereof
CA2747825A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
ES2692495T3 (es) 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013510829A (ja) * 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
JP5411366B2 (ja) 2009-12-16 2014-02-12 ノヴォ ノルディスク アー／エス 二重アシル化ｇｌｐ−１誘導体
AU2011208625C1 (en) 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
WO2012010553A1 (en) * 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
WO2012080471A1 (en) 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
HUE031405T2 (en) 2011-04-12 2017-07-28 Novo Nordisk As Double-acylated GLP-1 derivatives
RU2643515C2 (ru) 2011-12-29 2018-02-02 Ново Нордиск А/С Дипептид, содержащий непротеиногенную аминокислоту
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
HRP20231613T1 (hr) 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
CN104717972A (zh) 2012-10-17 2015-06-17 诺和诺德A/S（股份有限公司） 用于口服肽递送的脂肪酸酰化氨基酸
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
CN103304502B (zh) * 2013-06-02 2015-03-04 张远强 一类抗糖尿病化合物、其制备方法和用途
CN103304501B (zh) * 2013-06-02 2015-03-04 张远强 一类抗糖尿病化合物、其制备方法和用途
CN103304499B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
CN103304503B (zh) * 2013-06-02 2015-03-04 张远强 抗糖尿病化合物、其制备方法和用途
EP3013796B9 (en) * 2013-06-27 2020-07-01 LG Chem, Ltd. Biaryl derivatives as gpr120 agonists
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
KR20160075819A (ko) 2013-11-15 2016-06-29 노보 노르디스크 에이/에스 선택적 pyy 화합물 및 그것의 사용
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2016102562A1 (en) * 2014-12-23 2016-06-30 Novo Nordisk A/S Fgf21 derivatives and uses thereof
EP3307768B1 (en) 2015-06-12 2025-01-29 Novo Nordisk A/S Selective pyy compounds and uses thereof
US10905744B2 (en) 2015-10-07 2021-02-02 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN107589246B (zh) * 2017-03-07 2019-10-01 上海原科实业发展有限公司 一种纤维蛋白激活剂、其制备方法，包括该激活剂的试剂盒及采用该试剂盒的检测方法
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
EP3712164A4 (en) * 2017-11-14 2021-08-18 Senju Pharmaceutical Co., Ltd. PEPTIDE STABILIZED BY PACAP
MA53076B1 (fr) 2018-02-02 2023-11-30 Novo Nordisk As Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2019229242A1 (en) 2018-05-31 2019-12-05 Novo Nordisk A/S Derivatives comprising an apelin analogue and uses thereof
WO2020120463A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin conjugates
CN114901680B (zh) * 2019-12-30 2024-09-27 甘李药业股份有限公司 长效glp-1化合物
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物
JP7777085B2 (ja) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
US20240041983A1 (en) 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4423224A (en) * 1980-09-08 1983-12-27 Sds Biotech Corporation 4-Me-1-(2-(1H-tetrazol-5-yl)ethyl)benzene sulfonate and N-2-(1H-tetrazol-5-yl)ethyl methanesulfonamide
JPS604165A (ja) * 1983-06-21 1985-01-10 Taiho Yakuhin Kogyo Kk スルホニウム誘導体
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3626130A1 (de) * 1986-08-01 1988-02-11 Merck Patent Gmbh Aminosaeurederivate
WO1992001476A1 (en) 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US6492531B1 (en) * 1992-02-18 2002-12-10 Warner-Lambert Company Method of treating cognitive disorders
TW289757B (enExample) * 1993-05-08 1996-11-01 Hoechst Ag
US5776927A (en) * 1994-04-18 1998-07-07 Corvas International, Inc. Methionine sulfone and S-substituted cysteine sulfone derivatives as enzyme inhibitors
US5883107A (en) * 1994-06-17 1999-03-16 Corvas International, Inc. Arginine mimic derivatives as enzyme inhibitors
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DE19521653A1 (de) * 1995-06-14 1996-12-19 Hoechst Schering Agrevo Gmbh Substituierte Tetrazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
JPH09136878A (ja) 1995-09-12 1997-05-27 Ono Pharmaceut Co Ltd テトラゾール誘導体
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
JP2002514635A (ja) 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン耐性および高血糖の処置に有用なビフェニルオキソ−酢酸
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
US6337340B1 (en) * 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
DE60044041D1 (de) * 1999-01-14 2010-04-29 Amylin Pharmaceuticals Inc Exendine zur Glucagon Suppression
WO2002058690A2 (en) * 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
RU2258706C2 (ru) * 2001-02-20 2005-08-20 Чугаи Сейяку Кабусики Кайся Азолы в качестве ингибиторов малонил-соа-декарбоксилазы, полезные в качестве модуляторов метаболизма
EP1406872B1 (en) * 2001-06-20 2007-12-19 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2004537580A (ja) * 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
MXPA04002404A (es) * 2001-09-14 2004-05-31 Novo Nordisk As Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r.
NZ532209A (en) * 2001-11-30 2007-05-31 Pfizer Prod Inc Controlled release microparticle pharmaceutical composition for the sustained release of an EP2 receptor selective agonist for treating bone injury or bone defect
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US7351725B2 (en) * 2002-01-18 2008-04-01 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
TW200400035A (en) * 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
JP2005538953A (ja) * 2002-05-28 2005-12-22 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド 新規チオフェンアミジン、それらの組成物、および補体媒介疾患および病気を治療する方法
JP2005533774A (ja) 2002-06-07 2005-11-10 ランバクシー ラボラトリーズ リミテッド ジバルプロエクスソジウムの放出遅延剤
WO2003103653A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
US20070060748A1 (en) 2002-11-27 2007-03-15 Hamilton Gregory S Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
EP1567518B1 (en) * 2002-12-03 2009-01-14 Ciba Holding Inc. Oxime ester photoinitiators with heteroaromatic groups
ATE378063T1 (de) 2002-12-20 2007-11-15 Novo Nordisk As Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
EP1610812A1 (en) 2003-03-11 2006-01-04 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
US20050096466A1 (en) * 2003-09-19 2005-05-05 Schwinden Mark D. Process for the preparation of tetrazol-derived compounds as growth hormone secretagogues
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
EP2932981B1 (en) * 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
CN101665538A (zh) * 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP4933455B2 (ja) * 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
TWI596110B (zh) * 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物

Also Published As

Publication number Publication date
EP2289560A2 (en) 2011-03-02
WO2006005667A2 (en) 2006-01-19
US9061067B2 (en) 2015-06-23
US20090111730A1 (en) 2009-04-30
EP2292272A2 (en) 2011-03-09
EP2289560B1 (en) 2015-04-22
KR20070029247A (ko) 2007-03-13
JP2008507477A (ja) 2008-03-13
BRPI0512988A (pt) 2008-04-22
MXPA06015049A (es) 2007-02-08
US20120088716A1 (en) 2012-04-12
EP1765408A2 (en) 2007-03-28
EP1765408B1 (en) 2015-12-09
ES2542228T3 (es) 2015-08-03
WO2006005667A3 (en) 2006-10-12
CN101005857A (zh) 2007-07-25
EP2292272A3 (en) 2011-10-26
EP2289560A3 (en) 2011-10-19
AU2005261740A1 (en) 2006-01-19
RU2006144821A (ru) 2008-08-20
ES2564167T3 (es) 2016-03-18

Similar Documents

Publication Publication Date Title
EP2289560B1 (en) Polypeptide protracting tags comprising a tetrazole moiety
US7897560B2 (en) Plasma protein affinity tags
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
ES2532116T3 (es) Péptidos derivados con A-B-C-D y sus usos terapéuticos
JP5209463B2 (ja) アシル化ｇｌｐ−１化合物
EP2190873B1 (en) Truncated glp-1 derivatives and their therapeutical use
US20090005312A1 (en) Novel glp-1 analogues linked to albumin-like agents
MXPA06002941A (es) Derivados de enlace a albumina de peptidos terapeuticos.
CA2792663A1 (en) Novel glucagon analogues
CA2549582A1 (en) Novel glp-1 compounds
JP2008516621A (ja) 成長ホルモン結合体

Legal Events

Date Code Title Description
FZDE Discontinued